Emerging Role of miRNAs in the Drug Resistance of Gastric Cancer

Gastric cancer is the third leading cause of cancer mortality worldwide. Unfortunately, most gastric cancer cases are diagnosed in an advanced, non-curable stage and with a limited response to chemotherapy. Drug resistance is one of the most important causes of therapy failure in gastric cancer patients. Although the mechanisms of drug resistance have been broadly studied, the regulation of these mechanisms has not been completely understood. Accumulating evidence has recently highlighted the role of microRNAs in the development and maintenance of drug resistance due to their regulatory features in specific genes involved in the chemoresistant phenotype of malignancies, including gastric cancer. This review summarizes the current knowledge about the miRNAs’ characteristics, their regulation of the genes involved in chemoresistance and their potential as targeted therapies for personalized treatment in resistant gastric cancer.

[1]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[2]  H. Xiao,et al.  Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells , 2011, Acta Pharmacologica Sinica.

[3]  Cheng Huang,et al.  miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. , 2013, Toxicology.

[4]  Shivendra V. Singh,et al.  Inherent and Acquired Resistance to Paclitaxel in Hepatocellular Carcinoma: Molecular Events Involved , 2013, PloS one.

[5]  Adrian V. Lee,et al.  The type I insulin-like growth factor receptor pathway: a key player in cancer therapeutic resistance. , 2008, Frontiers in bioscience : a journal and virtual library.

[6]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[7]  R. Labianca,et al.  Gastric cancer. , 2009, Critical reviews in oncology/hematology.

[8]  Hai-jiang Wang,et al.  Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel , 2015, Cell Biochemistry and Biophysics.

[9]  R. Callaghan,et al.  P-glycoprotein retains function when reconstituted into a sphingolipid- and cholesterol-rich environment Published, JLR Papers in Press, July 16, 2004. DOI 10.1194/jlr.M400220-JLR200 , 2004, Journal of Lipid Research.

[10]  T. Qiao,et al.  Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. , 2007, Journal of experimental & clinical cancer research : CR.

[11]  J. Hickman,et al.  bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. , 1993, Cancer research.

[12]  B. Davidson,et al.  RNA polymerase III transcribes human microRNAs , 2006, Nature Structural &Molecular Biology.

[13]  Jun Wang,et al.  Delivery systems for siRNA drug development in cancer therapy , 2015 .

[14]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[15]  V. Baumann,et al.  miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. , 2014, Future medicinal chemistry.

[16]  Jing Wang,et al.  Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance , 2014, Genes & diseases.

[17]  Tao Jiang,et al.  Circulating microRNAs in cancer: origin, function and application , 2012, Journal of Experimental & Clinical Cancer Research.

[18]  Theresa A. Storm,et al.  Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways , 2006, Nature.

[19]  Lin Xia,et al.  Methylation of miR-129-5p CpG island modulates multi-drug resistance in gastric cancer by targeting ABC transporters , 2014, Oncotarget.

[20]  R. Parsons,et al.  The role of PTEN signaling perturbations in cancer and in targeted therapy , 2008, Oncogene.

[21]  M. Fromm.  The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. , 2002, Advanced drug delivery reviews.

[22]  Yang Liang,et al.  Sequence-specific inhibition of microRNA via CRISPR/CRISPRi system , 2014, Scientific Reports.

[23]  De-cai Yu,et al.  Circulating MicroRNAs: Potential Biomarkers for Cancer , 2011, International journal of molecular sciences.

[24]  Zicai Liang,et al.  Small indels induced by CRISPR/Cas9 in the 5′ region of microRNA lead to its depletion and Drosha processing retardance , 2014, RNA biology.

[25]  R. Qin,et al.  miR-449a Regulates Proliferation and Chemosensitivity to Cisplatin by Targeting Cyclin D1 and BCL2 in SGC7901 Cells , 2014, Digestive Diseases and Sciences.

[26]  V. Kim,et al.  The nuclear RNase III Drosha initiates microRNA processing , 2003, Nature.

[27]  C. Croce,et al.  MicroRNA expression and function in cancer. , 2006, Trends in molecular medicine.

[28]  Guoxin Zhang,et al.  MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7 , 2015, Journal of experimental & clinical cancer research : CR.

[29]  Yan Cheng,et al.  [Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer]. , 2014, Yi chuan = Hereditas.

[30]  B. Jiang,et al.  miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP , 2012, Cancer Chemotherapy and Pharmacology.

[31]  Thomas Tuschl,et al.  MicroRNAs in human cancer. , 2013, Advances in experimental medicine and biology.

[32]  Y. Sakamoto,et al.  The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab , 2013, Annals of Surgical Oncology.

[33]  Liu Hong,et al.  miR‐15b and miR‐16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells , 2008, International journal of cancer.

[34]  Q. Lu,et al.  MicroRNA‐106a induces multidrug resistance in gastric cancer by targeting RUNX3 , 2013, FEBS letters.

[35]  M. Dolan,et al.  Molecular mechanisms of resistance and toxicity associated with platinating agents. , 2007, Cancer treatment reviews.

[36]  Li Yang,et al.  MicroRNA-19a/b regulates multidrug resistance in human gastric cancer cells by targeting PTEN. , 2013, Biochemical and biophysical research communications.

[37]  V. Kim,et al.  Biogenesis of small RNAs in animals , 2009, Nature Reviews Molecular Cell Biology.

[38]  Min Zhang,et al.  Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres , 2008, BMC Cancer.

[39]  E. Lai,et al.  Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis , 2010, Proceedings of the National Academy of Sciences.

[40]  R. Altman,et al.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). , 2011, Pharmacogenetics and genomics.

[41]  David J Munroe,et al.  miRNA signature associated with outcome of gastric cancer patients following chemotherapy , 2011, BMC Medical Genomics.

[42]  R. Liu,et al.  miRNA27a Is a Biomarker for Predicting Chemosensitivity and Prognosis in Metastatic or Recurrent Gastric Cancer , 2014, Journal of cellular biochemistry.

[43]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[44]  P. Muti,et al.  miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer , 2012, Cell Death and Disease.

[45]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[46]  V. Solovyev,et al.  A novel type of RNase III family proteins in eukaryotes. , 2000, Gene.

[47]  Yue-Qin Chen,et al.  Circulating miRNAs in cancer: from detection to therapy , 2014, Journal of Hematology & Oncology.

[48]  Fangting Wu,et al.  Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines , 2014, Nucleic acids research.

[49]  Y. Chae,et al.  RNA interference-directed caveolin-1 knockdown sensitizes SN12CPM6 cells to doxorubicin-induced apoptosis and reduces lung metastasis , 2010, Tumor Biology.

[50]  I. Martins,et al.  Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[51]  I. MacRae,et al.  The molecular machines that mediate microRNA maturation , 2008, Journal of cellular and molecular medicine.

[52]  C. Croce,et al.  miRNAs, Cancer, and Stem Cell Division , 2005, Cell.

[53]  M. Pirmohamed,et al.  ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research , 2007, The Pharmacogenomics Journal.

[54]  K. Czaplinski,et al.  Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. , 2004, RNA.

[55]  Lin He,et al.  MicroRNAs: small RNAs with a big role in gene regulation , 2004, Nature reviews genetics.

[56]  Eric C Lai,et al.  Mirtrons: microRNA biogenesis via splicing. , 2011, Biochimie.

[57]  Eugene Berezikov,et al.  Mammalian mirtron genes. , 2007, Molecular cell.

[58]  Ye Zhang,et al.  miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1 , 2015, Tumor Biology.

[59]  E. Bellolio,et al.  The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance , 2014, Virchows Archiv.

[60]  Tongshan Wang,et al.  MiR‐503 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R and BCL2 , 2014, Chinese medical journal.

[61]  Thierry Buclin,et al.  Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance , 2004, Clinical pharmacology and therapeutics.

[62]  Min Liu,et al.  miR-23a Targets Interferon Regulatory Factor 1 and Modulates Cellular Proliferation and Paclitaxel-Induced Apoptosis in Gastric Adenocarcinoma Cells , 2013, PloS one.

[63]  Min Liu,et al.  MicroRNA‐23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin‐6 receptor , 2010, The FEBS journal.

[64]  W. Cho.  OncomiRs: the discovery and progress of microRNAs in cancers , 2007, Molecular Cancer.

[65]  Tongshan Wang,et al.  miR-20a enhances cisplatin resistance of human gastric cancer cell line by targeting NFKBIB , 2015, Tumor Biology.

[66]  Pick-Wei Lau,et al.  The Molecular Architecture of Human Dicer , 2012, Nature Structural &Molecular Biology.

[67]  Y. Shu,et al.  Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel , 2013, Cancer Chemotherapy and Pharmacology.

[68]  Hua-mei Tang,et al.  Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway. , 2010, Oncology reports.

[69]  Scott W. Lowe,et al.  Apoptosis A Link between Cancer Genetics and Chemotherapy , 2002, Cell.

[70]  A. Yu.  Small interfering RNA in drug metabolism and transport. , 2007, Current drug metabolism.

[71]  Y. Akao,et al.  Decreased Expression of MicroRNA-143 and -145 in Human Gastric Cancers , 2009, Oncology.

[72]  Ji-ping Wang,et al.  MiR-218 inhibits multidrug resistance (MDR) of gastric cancer cells by targeting Hedgehog/smoothened. , 2015, International journal of clinical and experimental pathology.

[73]  R. Qin,et al.  miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. , 2013, Acta biochimica et biophysica Sinica.

[74]  T. Fojo,et al.  The role of ABC transporters in clinical practice. , 2003, The oncologist.

[75]  H. Seitz,et al.  Structural determinants of miRNAs for RISC loading and slicer-independent unwinding , 2009, Nature Structural &Molecular Biology.

[76]  M. Volm,et al.  Intrinsic and Acquired Drug Resistance in Malignant Tumors , 2008, Arzneimittel-Forschung (Drug Research).

[77]  D. Bartel,et al.  MicroRNAs Modulate Hematopoietic Lineage Differentiation , 2004, Science.

[78]  Xia Shan,et al.  miR‐181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines , 2010, International journal of cancer.

[79]  Zebo Huang,et al.  Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGF1R and BCL2 , 2015, Tumor Biology.

[80]  Y. Shang,et al.  miR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2 , 2015, Cell Death and Disease.

[81]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[82]  T. Fojo.  Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[83]  Xi Chen,et al.  Role of microRNA in anticancer drug resistance , 2010, International journal of cancer.

[84]  A. Strasser,et al.  The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.

[85]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[86]  Y. Shang,et al.  miR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1 , 2014, Oncogene.

[87]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[88]  Wei Zhu,et al.  miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2 , 2012, Medical Oncology.

[89]  Y. Shu,et al.  miR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and BCL2. , 2014, Anti-cancer agents in medicinal chemistry.